1. Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation
- Author
-
Peiris, Malalage N, Meyer, April N, Warda, Dalida, Campos, Alexandre Rosa, and Donoghue, Daniel J
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Biotechnology ,Hematology ,Lymphoma ,Rare Diseases ,Cancer ,2.1 Biological and endogenous factors ,Aetiology ,Cell Proliferation ,Chromosomes ,Human ,Pair 8 ,GRB2 Adaptor Protein ,Humans ,Myeloproliferative Disorders ,Proteomics ,Pyrazoles ,Pyrimidines ,Pyrroles ,Receptor ,Fibroblast Growth Factor ,Type 1 ,Translocation ,Genetic ,Ubiquitin-Specific Proteases ,chromosomal translocation ,oncogenic fusion protein ,phosphoproteome ,protein interactome ,stem cell leukemia/lymphoma ,Oncology and carcinogenesis - Abstract
Translocation of Fibroblast Growth Factor Receptors (FGFRs) often leads to aberrant cell proliferation and cancer. The BCR-FGFR1 fusion protein, created by chromosomal translocation t(8;22)(p11;q11), contains Breakpoint Cluster Region (BCR) joined to Fibroblast Growth Factor Receptor 1 (FGFR1). BCR-FGFR1 represents a significant driver of 8p11 myeloproliferative syndrome, or stem cell leukemia/lymphoma, which progresses to acute myeloid leukemia or T-cell lymphoblastic leukemia/lymphoma. Mutations were introduced at Y177F, the binding site for adapter protein Grb2 within BCR; and at Y766F, the binding site for the membrane associated enzyme PLCγ1 within FGFR1. We examined anchorage-independent cell growth, overall cell proliferation using hematopoietic cells, and activation of downstream signaling pathways. BCR-FGFR1-induced changes in protein phosphorylation, binding partners, and signaling pathways were dissected using quantitative proteomics to interrogate the protein interactome, the phosphoproteome, and the interactome of BCR-FGFR1. The effects on BCR-FGFR1-stimulated cell proliferation were examined using the PLCγ1 inhibitor U73122, and the irreversible FGFR inhibitor futibatinib (TAS-120), both of which demonstrated efficacy. An absolute requirement is demonstrated for the dual binding partners Grb2 and PLCγ1 in BCR-FGFR1-driven cell proliferation, and new proteins such as ECSIT, USP15, GPR89, GAB1, and PTPN11 are identified as key effectors for hematopoietic transformation by BCR-FGFR1.
- Published
- 2022